Hip fracture
Drug research and approvals for hip fracture: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 118 studies of hip fracture are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 118
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 2
- Geriatric Hip Fracture mFI-5 for Postoperative ICU Need and 30 Day MortalityNCT07936279 · Not reported · Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · starts Jul 1, 2026
- Monitored Anesthesia Care and Soft Tissue Infiltration With Local Anesthesia Feasibility TrialNCT07897656 · Not applicable · NYU Langone Health · starts Oct 27, 2026
- Dexmedetomidine for Prevention of Delirium After Hip Fracture SurgeryNCT07867899 · Not reported · Peter Gaarsdal Uhrbrand · starts Oct 1, 2026
- Total Intravenous Versus Inhalational Anesthesia in Patients Undergoing Hip Fracture SurgeryNCT07860996 · Not reported · Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital · starts Sep 30, 2026
- Cohort Study on the Prognosis and Influencing Factors in Elderly Patients With Hip Fractures in Multicenter of ChinaNCT07847164 · Not reported · Beijing Hospital · starts Dec 1, 2024
- Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis StemNCT07828080 · Not applicable · Seoul National University Bundang Hospital · starts Jun 18, 2025
- Bone Marrow Injection in Fracture of Femoral NeckNCT07808294 · Not applicable · Yaser Alkanash · starts May 12, 2025
- CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELiriumNCT07804498 · Phase 2 · University of Milano Bicocca · starts Jun 3, 2026
- A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I TrialNCT07740239 · Not reported · Tampere University Hospital · starts Nov 13, 2024
How its trials ended
731 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 125 whose ending is known, 29% met their primary endpoint, 10% missed it and 62% stopped early.
- Completed, result not reported30942%
- Ongoing15421%
- Status unknown14320%
- Stopped: other or unclear416%
- Met its primary endpoint365%
- Stopped: enrollment or feasibility233%
- Missed its primary endpoint122%
- Stopped: sponsor or business decision61%
- Stopped: lack of efficacy51%
- Stopped: funding2<1%
| Oct 16, 2023 | Hip fracture oral thromboprophylaxis: a pilot randomized controlled trial (hip pro pilot)Rivaroxaban / Acetylsalicylic acid | Governors of The University of Calgary | Ongoing |
| Mar 23, 2016 | Topical tranexamic acid (TXA) in hip fractures, a double-blind randomized controlled trialTranexamic acid | Sault Area Hospital | Ongoing |
| Feb 3, 2015 | Direct-application of tranexamic acid for hip fracture: a randomized controlled trialTranexamic acid | University Health Network | Pending |
| Apr 15, 2005 | AclastaZoledronic acid | Sandoz Pharmaceuticals d.d. | EMA ↗ |
| Mar 20, 2002 | ArixtraFondaparinux sodium | Viatris Healthcare Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA